Automation & Digitisation
Cell Therapy
Gene Therapy

Phacilitate Automation Working Groups Key Outcomes

Phacilitate
18 March 2021
SHARE NOW

what were the outcomes of our latest phacilitate automation working groups?

At our latest Automation Working Groups, we brought together two groups of industry leaders to discuss the key challenges currently faced by the advanced therapies sector. 

Led by both a Rapporteur & Co-Rapporteur, each of the groups were given specific topics to consider, with experts representing various perspectives. The aim of the discussions was to develop tangible outcomes to aid the industry, and tackle the challenges that Automation creates in the advanced therapies space.

The notes from the Working Groups have now been compiled into two, handy reports which you can explore below…

How Robust Does Your IPC/QC Strategy Have to Be When Manufacturing Advanced Therapies at Scale?

This working group session, led in partnership with Miltenyi Biotec, was geared towards Heads of Manufacturing and of IPC/QC, process development partners, standards representatives and collaboration partners, such as IPC and QC technology companies. The closed door session was led by:

Nicolas Danzenbacher

Rapporteur:

Nicolas Danzenbächer

Senior Product Manager, MACS GMP CYtokines and Cell Culture Reagents

Miltenyi Biotec

Shashi Murthy

Co-Rapporteur:

Shashi Murthy

CTO

Flaskworks/Northwest Biotherapeutics

Download link: https://drive.google.com/file/d/1y66PRgiq-pxdLX6akeK7z3yhQ0ONShly/view?usp=sharing

Automation’s Speed Limit?

Critical steps to balance technology advancements, a well-regulated industry and therapeutic speed to market

This working group session, led in partnership with MilliporeSigma, brought together biotech and technology innovators – stakeholders from both sides of the fence – to discuss the necessary steps for the partnership to serve both sides while supporting compliant automation. The closed door session was led by:

Nicolas Danzenbacher

Rapporteur:

Dr. Nina Bauer

Head of Commercial, Gene Editing and Novel Modalities

MilliporeSigma

Shashi Murthy

Co-Rapporteur:

Ken Kotz

Director Drug product Enabling Technologies

bluebird bio

Download link: https://drive.google.com/file/d/1BXt8AhVSYc68YTy4G7gOFkKtEiMCn8X0/view?usp=sharing